Humanigen Inc. (HGEN) Expands its anti-GM-CSF Patent Portfolio

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. LLY
4. TSLA
5. META
6. FICO
7. ACCV
8. SPCX
9. MSFT
10. AZN

Go back to Humanigen Inc. (HGEN) Expands its anti-GM-CSF Patent Portfolio

Humanigen Expands its anti-GM-CSF Patent Portfolio

March 2, 2021 7:00 AM EST

First patent issued for the use of lenzilumab to reduce non-GM-CSF cytokines/chemokines that contribute to immunotherapy-related toxicity Second patent issued for the use of lenzilumab to improve the efficacy and durability of immunotherapy

BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (Humanigen) a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced the company has been awarded two patents by the United States Patent and Trademark Office (USPTO). These two patents expand... More